ArticleWorld journal of surgical oncology2015
The Manchester guidelines for contralateral risk-reducing mastectomy.
Article in World journal of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Influence of Variant of Uncertain Significance (VUS) Genetic Testing Results on Mastectomy Choice in Lumpectomy-Eligible Patients.Annals of surgical oncology · 2026Article
- Risk-Reducing Mastectomy inJournal of breast cancer · 2026Review
- Contralateral prophylactic mastectomy for unilateral breast cancer in Chinese female population: a retrospective cohort study.Gland surgery · 2023Article
- Trends in Radiation Dose to the Contralateral Breast During Breast Cancer Radiation Therapy.Radiation research · 2023Article
- EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.European journal of cancer (Oxford, England : 1990) · 2023Review
- The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk inCancers · 2023Article
- Analysis of a Trend Reversal in US Lumpectomy Rates From 2005 Through 2017 Using 3 Nationwide Data Sets.JAMA surgery · 2022Observational
- CBCRisk-Black: a personalized contralateral breast cancer risk prediction model for black women.Breast cancer research and treatment · 2022Article
- The risk of contralateral breast cancer: a SEER-based analysis.British journal of cancer · 2021Article
- The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer.Scientific reports · 2021Article
- Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer.NPJ breast cancer · 2020Article
- Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.Breast cancer research and treatment · 2020Article
- Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy.Annals of surgical oncology · 2020Article
- Prediction and clinical utility of a contralateral breast cancer risk model.Breast cancer research : BCR · 2019Article
- Validation of a personalized risk prediction model for contralateral breast cancer.Breast cancer research and treatment · 2018Article
- Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.Breast cancer research and treatment · 2018Article
- Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England.Annals of the Royal College of Surgeons of England · 2016Article
- Contralateral breast cancer in patients carrying mutations in the BRCA1∕2 gene.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRates of contralateral risk-reducing mastectomy (CRRM) are rising, despite a decreasing global incidence of contralateral breast cancer. Reasons for requesting this procedure are complex, and we have previously shown a variable practice amongst breast and plastic surgeons in England. We propose a protocol, based on a published systematic review, a national UK survey and the Manchester experience of CRRM.
methodsWe reviewed the literature for risk factors for contralateral breast cancer and have devised a 5-step process that includes history taking, calculating contralateral breast cancer risk, cooling off period/counselling, multi-disciplinary assessment and consent. Members of the multi-disciplinary team included the breast surgeon, plastic surgeon and geneticist, who formulated guidelines.
resultsA simple formula to calculate the life-time risk of contralateral breast cancer has been devised. This allows stratification of breast cancer patients into different risk-groups: low, above average, moderate and high risk. Recommendations vary according to different risk groups.
conclusionThese guidelines are a useful tool for clinicians counselling women requesting CRRM. Risk assessment is mandatory in this group of patients, and our formula allows evidence-based recommendations to be made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.